Overview

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
TG Therapeutics
Treatments:
Rituximab